Profund Advisors LLC cut its holdings in shares of Thermo Fisher Scientific Inc. (NYSE:TMO) by 1.5% during the fourth quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 9,277 shares of the medical research company’s stock after selling 137 shares during the period. Profund Advisors LLC’s holdings in Thermo Fisher Scientific were worth $4,321,000 at the end of the most recent reporting period.
Several other institutional investors have also made changes to their positions in TMO. Avenue 1 Advisors LLC acquired a new stake in Thermo Fisher Scientific during the 4th quarter worth $239,000. Rothschild & Co. Asset Management US Inc. boosted its stake in shares of Thermo Fisher Scientific by 59.8% during the fourth quarter. Rothschild & Co. Asset Management US Inc. now owns 207,245 shares of the medical research company’s stock worth $96,531,000 after buying an additional 77,558 shares during the period. Greenleaf Trust grew its holdings in shares of Thermo Fisher Scientific by 2.0% during the fourth quarter. Greenleaf Trust now owns 10,263 shares of the medical research company’s stock worth $4,780,000 after buying an additional 201 shares during the last quarter. CIBC World Markets Inc. increased its position in Thermo Fisher Scientific by 12.8% in the 4th quarter. CIBC World Markets Inc. now owns 39,224 shares of the medical research company’s stock valued at $18,270,000 after acquiring an additional 4,463 shares during the period. Finally, Resource Management LLC raised its stake in Thermo Fisher Scientific by 13.8% during the 4th quarter. Resource Management LLC now owns 1,644 shares of the medical research company’s stock valued at $766,000 after acquiring an additional 199 shares during the last quarter. 87.17% of the stock is currently owned by institutional investors and hedge funds.
Shares of NYSE:TMO opened at $463.28 on Tuesday. The company has a current ratio of 2.93, a quick ratio of 2.31 and a debt-to-equity ratio of 0.66. The firm has a market cap of $183.61 billion, a price-to-earnings ratio of 37.97, a PEG ratio of 1.40 and a beta of 0.85. The stock’s 50-day moving average price is $500.86 and its two-hundred day moving average price is $464.08. Thermo Fisher Scientific Inc. has a 12-month low of $250.21 and a 12-month high of $532.57.
Thermo Fisher Scientific announced that its Board of Directors has initiated a share repurchase plan on Thursday, November 5th that authorizes the company to repurchase $2.50 billion in outstanding shares. This repurchase authorization authorizes the medical research company to reacquire up to 1.2% of its stock through open market purchases. Stock repurchase plans are generally an indication that the company’s board believes its stock is undervalued.
In other news, COO Mark Stevenson sold 14,133 shares of the firm’s stock in a transaction dated Monday, December 7th. The stock was sold at an average price of $473.84, for a total transaction of $6,696,780.72. Following the completion of the sale, the chief operating officer now directly owns 58,005 shares in the company, valued at $27,485,089.20. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders own 0.44% of the company’s stock.
A number of research analysts have recently issued reports on the company. Cowen boosted their target price on Thermo Fisher Scientific from $525.00 to $585.00 and gave the company an “outperform” rating in a report on Tuesday, February 2nd. Smith Barney Citigroup cut shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating in a research note on Wednesday, December 16th. Citigroup Inc. 3% Minimum Coupon Principal Protected Based Upon Russell downgraded shares of Thermo Fisher Scientific from a “buy” rating to a “neutral” rating and cut their price objective for the stock from $550.00 to $500.00 in a research report on Wednesday, December 16th. KeyCorp started coverage on shares of Thermo Fisher Scientific in a research note on Monday, November 9th. They set a “sector weight” rating and a $550.00 price target on the stock. Finally, Zacks Investment Research cut shares of Thermo Fisher Scientific from a “buy” rating to a “hold” rating and set a $488.00 price target for the company. in a report on Tuesday, December 22nd. Five investment analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. Thermo Fisher Scientific presently has an average rating of “Buy” and a consensus target price of $527.47.
About Thermo Fisher Scientific
Thermo Fisher Scientific Inc provides analytical and other instruments, laboratory equipment, software, consumables, reagents, instrument systems, chemicals, supplies, and services worldwide. The company's Life Sciences Solutions segment offers reagents, instruments, and consumables for biological and medical research, discovery and production of drugs and vaccines, and diagnosis of diseases to pharmaceutical, biotechnology, agricultural, clinical, academic, and government markets.
See Also: Back-End Load
Want to see what other hedge funds are holding TMO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Thermo Fisher Scientific Inc. (NYSE:TMO).
Receive News & Ratings for Thermo Fisher Scientific Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Thermo Fisher Scientific and related companies with MarketBeat.com's FREE daily email newsletter.